

## REMARKS

Claims 71 to 75 have been added prior to examination of this application on its merits. Support for this can be found in the specification, for example, on page 22, lines 19-21. No new matter has been added.


The Office Action has required restriction under 35 U.S.C. § 121, alleging that two distinct inventions are presented by claims 1-70. These have been identified as follows:

Group I – claims 1-35; and

Group II – claims 36-70.

Although Applicant respectfully disagrees, Applicant elects, with traverse, to prosecute claims of Group I. Claims 71-75 are included in Group I as they refer to generic formula I. Accordingly, Applicant elects to prosecute claims 1-35 and 71-75.

Furthermore, Applicant elects the following species for search purposes:



which is Compound I on page 17.


Applicant submits that claims 1-35 and 71-75 read on the elected species.

The Office Action further requires that Applicant elect one specific anti-proliferative agent. It is understood that this is merely for search purposes and that Applicant will be entitled to additional anti-proliferative agents upon allowance of a generic claim. Applicant elects capecitabine of newly added claims 71-74.

If any fee due is not accounted for herein, please charge such fee to Deposit Account No. 19-3880. If any extension of time is required and not petitioned for, such extension is hereby petitioned for, and it is requested that any fee due in connection therewith be charged to the aforementioned Deposit Account.

Applicant respectfully requests that the Restriction Requirement be withdrawn in view of the foregoing remarks, and an early action on the merits be provided.

Respectfully submitted,



Rena Patel, Ph.D.  
Attorney for Applicant  
Reg. No. 41,412

Date: **May 22, 2003**

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5398